AstraZeneca is working on strengthening its oncology product portfolio through label expansions of existing products and progressing oncology pipeline candidates.

AstraZeneca expects continued growth of its oncology medicines in 2025, particularly Tagrisso, Enhertu, Merck-partnered Lynparza and Imfinzi, despite the incremental impact of the Part D redesign.

VANCOUVER, BC / ACCESS Newswire / June 27, 2025 / Onco-Innovations Limited (CBOE CA: ONCO) (Frankfurt: W1H,WKN: A3EKSZ) (" Onco " or the " Company ") is pleased to announce that its wholly-owned ...

ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost top-line growth.

Onco-Innovations Welcomes AstraZeneca's Interest in Founding Role in PROmAI - an Inka-led AI-Oncology Consortium ACCESS Newswire - Fri Jun 27, 1:00PM CDT ...

Onco-Innovations Welcomes AstraZeneca's Interest in Founding Role in PROmAI - an Inka-led AI-Oncology Consortium ...

PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.

Merck’s key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca.